Celldex Therapeutics Presents Positive 12 Week Results from

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...

Related Keywords

United States , Berlin , Germany , American , Sarah Cavanaugh , Allen Kaplan , Anthonys Marucci , Marcus Maurer , Corporate Affairs Administration , Company Contact , Company Phase , Celldex Therapeutics Inc , Nasdaq , American Academy Of Allergy , Globenewswire Inc , Celldex Therapeutics , Annual Meeting , Chief Executive Officer , Clinical Activity Assessments , Confidence Interval , Complete Control , Private Securities Litigation Reform Act , Vice President , Corporate Affairs , Markets ,